Legend Biotech reported its first profitable quarter, with adjusted net income of $63 million in the second quarter, driven by demand for Carvykti. The company also detailed a leadership shift: CEO Ying Huang resigned in late July to lead K2 Therapeutics, and interim CEO Alan Bash took over while Legend searches for a permanent successor. The profitability milestone arrives as Legend manages a more competitive CAR-T environment. Analysts are focused on the potential pressure from off-the-shelf bispecifics and Gilead’s expected entry with anito-cel in autologous CAR-T. Legend said it expects to sustain profitability through the second half of 2026 and framed the interim transition around execution and accelerating its pipeline. It also reiterated the strength of its partnership with Johnson & Johnson amid new data advances from J&J’s Tecvayli-based combinations. For the CAR-T sector, the quarter underscores how commercially mature cell therapies are now navigating next-cycle competition and community scaling challenges.